CELLINK and AXT Join Forces to Expand Access to Innovative Bioprinting Technologies in Oceania
CELLINK, a global leader in 3D bioprinting technologies, is pleased to announce the signing of a distribution agreement with AXT, a prominent player within the scientific equipment landscape in Australia and the wider Oceania region. This strategic collaboration bolsters CELLINK’s growing presence in the region and represents another milestone in their ongoing expansion efforts.
(July 25, Gothenburg) CELLINK, a global leader in 3D bioprinting technologies, is pleased to announce the signing of a distribution agreement with AXT, a prominent player within the scientific equipment landscape in Australia and the wider Oceania region. This strategic collaboration represents another milestone in CELLINK’s ongoing expansion efforts, and will bring their bioprinting technologies into more researchers’ hands in Australia and New Zealand.
With this partnership, CELLINK aims to further enable researchers in Australia and New Zealand with cutting-edge bioprinting solutions, empowering them to advance their scientific endeavours and create the future of healthcare. By combining CELLINK’s state-of-the-art bioprinters and bioinks with ATX’s extensive distribution network and expertise, this collaboration promises to accelerate the adoption of bioprinting technologies across the region.
“We are thrilled to partner with AXT and expand our collaborator network within region. Through this partnership we are confident we will continue to support the growing user base in the region,” said Tomoko Bylund, Head of Sales APAC, CELLINK. “AXT’s reputation for excellence, dedication to customer success and their strong presence in the Australian market make them an ideal partner for us. We believe this collaboration will not only benefit researchers in Australia but also contribute to the advancement of the entire bioprinting field.”
AXT, known for its commitment to providing high-quality scientific equipment, is equally excited about the partnership. “We are honoured to be working with CELLINK, a truly innovative company at the forefront of bioprinting technologies,” said Richard Trett, CEO, AXT. “This collaboration enables us to offer our customers access to CELLINK’s impressive range of bioprinters and bioinks, allowing them to pursue ground-breaking research and drive significant advancements in the field of regenerative medicine.”
The distribution agreement between CELLINK and AXT is expected to bolster CELLINK’s presence in the Oceania region and strengthen its position as a leading provider of bioprinting solutions worldwide. By combining CELLINK’s cutting-edge technology with AXT’s local expertise and support, researchers in Australia and New Zealand will be empowered to create ground-breaking tissue and organ models, facilitating discoveries that could revolutionize personalized medicine and patient care.
For further information, please contact:
Avijit Minocha, Head of Marketing, CELLINK
Phone: +1 617 637 5372
CELLINK is enabling the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to push the boundaries of how 3D bioprinting can contribute to the future of health. Visit www.cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.